Dr. Sang-Mo Kang, MD

Dr. Kang practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Kang's NPI, 1003870007, was assigned on April 14, 2006. Dr. Kang graduated from Harvard Medical School in 1992. Dr. Kang holds California license G78412.

Dr. Kang's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Kang's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Medical Group. Dmand AI also links Dr. Kang to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kang practices, 3 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Kang's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Kang is board certified in surgery by the American Board of Surgery. Dr. Kang is licensed in California.

Dmand AI lists kidney transplant among the conditions Dr. Kang treats.

CMS data shows 160 Medicare services from Dr. Kang across 5 procedure codes in 2024, for 84 Medicare patients. Medicare paid $38,466 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 84 Medicare patients who saw Dr. Kang in 2024. The largest group is 65 to 74, with 41 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 60% are also on Medicaid. Their average risk score is 6.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kang's median patient age at 57, with 55% women.

In 2024, Dr. Kang wrote 120 Medicare Part D claims for 28 patients. 85% of them were for generic drugs. CMS names the drug for 43 of them, across 3 drugs with 11 or more claims each, at $275 in total drug cost. In 2023, CMS named 41 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Kang for performance year 2024, reported as part of a group. Dr. Kang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kang as offering telehealth.

Leg revascularization (restoring blood flow): 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 37 papers to Dr. Kang, published from 2007 to 2022. 2011 was the busiest year, with 3. The most frequent topics are Kidney Transplantation, Graft Survival and Graft Rejection. Dr. Kang has published most often in Am J Transplant. Dr. Kang's most frequent co-authors are Peter G. Stock, MD, Chris E. Freise, MD and Sandy Feng, MD.

Dmand AI links Dr. Kang to 13 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Kidney Diseases.

CMS Open Payments shows 10 general payments to Dr. Kang from 6 drug and device companies from 2016 to 2023. Education make up the largest share, 84% of the total. Intuitive Surgical, Inc. paid the most, $2,544.

Dmand AI lists 3 awards for Dr. Kang, most recently CMS Stage 1 EHR in 2013.

Dr. Kang graduated from Harvard Medical School in 1992. Dr. Kang is a member of ACS.

Dr. Kang is in network with 10 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.